Replimune Group (REPL) vs Vir Biotechnology (VIR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Replimune Group (REPL) has outperformed Vir Biotechnology (VIR) over the past year, gaining 107.3% versus a gain of 47.7%. Over five years, REPL leads with a -34.2% price change compared with -76.7% for VIR. Replimune Group is the larger company by market cap ($1.81 billion vs $1.56 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | REPL | VIR |
|---|---|---|
| Share price | $19.07 | $8.39 |
| Market cap | $1.81B | $1.56B |
| 1-day change | -0.83% | -5.41% |
| YTD return | +96.19% | +39.14% |
| 1-year return | +107.28% | +47.71% |
| 5-year return | -34.24% | -76.69% |
| EPS (TTM) | $-2.79 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $68.56M |
| Revenue growth (YoY) | — | -7.61% |
| Net income (latest FY) | $-313.94M | $-437.99M |
| Gross margin | — | 99.96% |
| Operating margin | — | -699.18% |
| Net margin | — | -638.87% |
| 52-week high | $23.54 | $14.38 |
| 52-week low | $1.50 | $5.45 |
| Distance from 52-week high | -18.99% | -41.66% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +33.72% | +178.67% |
| Average volume | 2.48M | 2.45M |
| Shares outstanding | 94.80M | 186.27M |
| Employees | 465 | 367 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed VIR by 59.6 percentage points over the past year.
About Replimune Group
REPL stock →Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 465 employees
About Vir Biotechnology
VIR stock →Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 367 employees
REPL vs VIR FAQ
Which is bigger, Replimune Group or Vir Biotechnology?
Replimune Group (REPL) is larger, with a market capitalization of $1.81B compared with $1.56B for Vir Biotechnology (VIR).
Which stock has performed better over the past year, REPL or VIR?
REPL returned +107.28% over the past 12 months, compared with +47.71% for VIR (price return, excluding dividends). Past performance does not predict future results.
Are Replimune Group and Vir Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.